To Know more how you can benefit from the Muslim Times, go to our Homepage or About Us page
Novavax Inc. began human testing of its coronavirus vaccine candidate and anticipates providing a first look in July at what sort of immune responses are generated.
In the first phase, 130 healthy adult volunteers at two sites in Australia will get two doses of NVX-CoV2373, the biotech’s experimental vaccine. If initial results look promising, the company plans to quickly move into the second phase — expand testing to other countries and age groups outside of 18 to 59.
The Gaithersburg, Maryland-based company is one of about 10 that are testing vaccines, according to the World Health Organization. Moderna Inc. reported the first Covid-19 vaccine results in humans last week.
The best of the Muslim Times’ collection for war against Covid 19:
In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.
Prime Minister Shinzo Abe says more than 30 countries have asked Japan for favipiravir (Avigan) to fight Covid 19
For the latest news about drugs and vaccines’ trials please go to: Pharmaceutical-Technology
Kaiser Permanente launches first coronavirus vaccine trial
Corona Fear’s Cure: Chanting from the Bible and the Quran
Can You Chant from the Bible or the Quran to Bliss and Happiness?
Japanese flu drug ‘clearly effective’ in treating coronavirus, says China
Synthetic antibodies might offer a quick coronavirus treatment
The Four Possible Timelines for Life Returning to Normal
The Muslim Times Recommending Universal BCG Vaccination to Fight the Pandemic
Coronavirus: TB Vaccination Trial Started in Melbourne, Australia
The Muslim Times has the best collections in the war against Covid 19 as we are collecting from all the established sources
All of humanity are intimate neighbors: Coronavirus proves it once again
Praise be to God for the Miracle of Our Immune System
USA: 15-minute coronavirus test is here
Does the Ordinary Soap Kill Coronavirus?
Here’s a list of disinfectants you can use against coronavirus
For the number of cases and epidemiology in each country go to: WorldOMeters
Categories: The Muslim Times, Vaccine
Biotech Novavax (NVAX) has announced that the U.S. Department of Defense (DoD) will provide up to $60 million in funding to assist with the manufacturing of NVX‑CoV2373, Novavax’s COVID-19 vaccine candidate. Shares are currently surging 15% in Friday’s pre-market trading.
The news comes after the company failed to make the cut as one of the five COVID-19 vaccine finalists selected for the Trump administration’s Operation Warp Speed project.
NVX‑CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS‑CoV‑2, the virus that causes COVID-19 disease. It consists of a stable, prefusion protein antigen made using the company’s proprietary nanoparticle technology and Matrix‑M adjuvant.
According to Novavax, the funding will help support its production of several components of the vaccine that will be manufactured in the U.S.
The agreement includes a 2020 delivery of 10 million doses of NVX‑CoV2373 for DoD that could be used in Phase 2/3 clinical trials or under an Emergency Use Authorization (EUA) if approved by the U.S. FDA.